GlassScriptPhysician profile
Dallin Stephens Walker
NPI 1588124366
$2,584.28
in general payments reported to CMS, 2019-2025
25 companies · $930 in 2025
The $930 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $59.98 · 2023: $503 · 2024: $1,091 · 2025: $930.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,524.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,524.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $489.71 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $458.57 | 2023-2025 | Vraylar, Ubrelvy |
| Lilly USA, LLC | $403.91 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $193.67 | 2023-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $180.13 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $157.98 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Daiichi Sankyo INC. | $149.10 | 2024-2025 | Injectafer |
| Glaxosmithkline, LLC. | $76.50 | 2023-2025 | Shingrix, Arexvy |
| Bioventus LLC | $47.32 | 2022-2023 | Durolane |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.77 | 2023-2024 | Ofev, Jardiance, Synjardy |
| Dynavax Technologies Corporation | $46.19 | 2025 | Heplisav-B |
| Viiv Healthcare Company | $37.57 | 2024 | Apretude |
| Currax Pharmaceuticals LLC | $36.06 | 2023-2024 | Contrave, Onzetra Xsail |
| Otsuka America Pharmaceutical, INC. | $33.29 | 2023 | Nuedexta |
| Bayer Healthcare Pharmaceuticals INC. | $32.49 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $32.23 | 2025 | |
| Gilead Sciences, INC. | $28.57 | 2024 | |
| Inspire Medical Systems, INC. | $21.91 | 2025 | Inspire |
| Sumitomo Pharma America, INC. | $20.08 | 2024 | Gemtesa |
| Tactile Systems Technology INC | $19.53 | 2024 | Flexitouch Plus, Entre Plus |
| Agios Pharmaceuticals, INC. | $17.52 | 2025 | Pyrukynd |
| Exact Sciences Corporation | $14.30 | 2025 | The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $14.13 | 2023 | |
| Dexcom, INC. | $13.60 | 2022 | |
| Merck Sharp & Dohme LLC | $13.15 | 2024 | Gardasil, Gardasil 9, Capvaxive |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dallin Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.